Abstract
Dulaglutide is a GLP-1 receptor agonist administered in a subcutaneous injection once weekly using prefilled injector. It is used for the treatment of adult patients with type 2 diabetes mellitus either in monotherapy or in combination with other types of antidiabetic medications.
In addition to good antidiabetic efficacy, positive effects of dulaglutide also include body weight and blood pressure reductions with a minimal increase in the risk of hypoglycaemia. The most frequent side effects of dulaglutide are gastrointestinal including nausea, vomiting and diarrhoea.
Their frequency and severity usually subside with longer duration of treatment.